Search results for "Complement membrane attack complex"

showing 10 items of 21 documents

Complement Activation in Peritoneal Dialysis–Induced Arteriolopathy

2017

Cardiovascular disease (CVD) is the leading cause of increased mortality in patients with CKD and is further aggravated by peritoneal dialysis (PD). Children are devoid of preexisting CVD and provide unique insight into specific uremia- and PD-induced pathomechanisms of CVD. We obtained peritoneal specimens from children with stage 5 CKD at time of PD catheter insertion (CKD5 group), children with established PD (PD group), and age-matched nonuremic controls (n=6/group). We microdissected omental arterioles from tissue layers not directly exposed to PD fluid and used adjacent sections of four arterioles per patient for transcriptomic and proteomic analyses. Findings were validated in omenta…

MaleVascular Endothelial Growth Factor A0301 basic medicinePathologyProteomemedicine.medical_treatmentComplement Membrane Attack ComplexSmad2 ProteinSeverity of Illness IndexTransforming Growth Factor betaMedicinePhosphorylationChildComplement ActivationCatheter insertionGeneral MedicineArteriosclerosisArteriolesComplement C3dNephrologyChild PreschoolFemaleOmentumPeritoneal DialysisSignal Transductionmedicine.medical_specialtyAdolescentPeritoneal dialysis03 medical and health sciencesDownregulation and upregulationClinical ResearchTGF beta signaling pathwayHumansSmad3 ProteinVascular DiseasesUremiabusiness.industryVascular diseaseComplement C1qInfant NewbornInfantComplement System Proteinsmedicine.diseaseUremiaComplement systemGene Ontology030104 developmental biologyCase-Control StudiesKidney Failure ChronicTranscriptomebusinessJournal of the American Society of Nephrology
researchProduct

CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions

1992

Blood cells express a cell membrane protein, termed homologous restriction factor 20 (HRF20) and identical to CD59, that can inhibit complement C5b-9 insertion into their membranes. In this report, we investigated by immunohistochemistry whether CD59 was present on cells in human atherosclerotic lesions since membranous C5b-9(m) has been found in lesions. Using a monoclonal anti-CD59 antibody, a cellular CD59 staining pattern was apparent in nearly all lesion specimens. CD59 stain co-localised with macrophage (CD14), T lymphocyte (CD7), endothelial cell (anti-factor VIII related antigen) and smooth muscle cell cytoskeletal-specific antigens (anti-alpha actin and muscle myosin). Endothelial …

Pathologymedicine.medical_specialtyCell typeArteriosclerosisCD59 Antigenschemical and pharmacologic phenomenaComplement Membrane Attack ComplexMyosinsBiologyAntigenAntigens CDMyosinmedicineHumansMacrophageSaphenous VeinActinComplement Inactivator ProteinsMembrane GlycoproteinsImmunohistochemistryActinsEndothelial stem cellCarotid ArteriesCD59 antigenEndothelium VascularCardiology and Cardiovascular MedicineComplement membrane attack complexAtherosclerosis
researchProduct

Expression of the human complement C8 subunits is independently regulated by interleukin 1β, interleukin 6, and interferon γ

1998

The eighth component of human complement (C8) is composed of two subunits which are products from three separate genes. The alpha-gamma- and the beta-subunit of C8 are expressed independently, and are part of the membrane attack complex. C8 is primarily synthesized in the liver. It has been shown in previous studies that the human hepatoma cell line HepG2 constitutively expresses C8, and thus is a suitable model system for studying C8 biosynthesis in vitro. Expression is modulated by the cytokines IL-1 beta, IL-6 and IFN-gamma. The effect of the different cytokines on the expression of these subunits was examined using biosynthetical labelling and immunoprecipitation methods. C8 alpha-gamma…

PharmacologybiologyInterleukin-6ImmunoprecipitationAntineoplastic AgentsSulfur RadioisotopesComplement C8Precipitin TestsMolecular biologyIn vitroComplement systemInterferon-gammaGene expressionTumor Cells Culturedbiology.proteinHumansSecretionInterleukin 6Beta (finance)Complement membrane attack complexInterleukin-1Immunopharmacology
researchProduct

Complement and Atherogenesis

1999

Abstract —Complement activation occurs in temporal correlation with the subendothelial deposition of LDL during early atherogenesis, and complement also plays a pathogenetic role in promoting lesion progression. Two lesion components have been identified that may be responsible for complement activation. First, enzymatic degradation of LDL generates a derivative that can spontaneously activate complement, and enzymatically degraded LDL (E-LDL) has been detected in the lesions. Second, C-reactive protein (CRP) colocalizes with complement C5b-9, as evidenced by immunohistological studies of early atherosclerotic lesions, so the possibility exists that this acute phase protein also fulfills a…

PhosphorylcholineNeuraminidaseComplement Membrane Attack ComplexCoronary Artery DiseaseBiologyPhospholipaseLesionPathogenesismedicineHumansElectrophoresis Gel Two-DimensionalTrypsinComplement Activationchemistry.chemical_classificationPhosphorylcholineC-reactive proteinAcute-phase proteinCholesterol LDLComplement C3Coronary VesselsMolecular biologyComplement systemC-Reactive ProteinEnzymeBiochemistrychemistryType C Phospholipasesbiology.proteinCalciummedicine.symptomCardiology and Cardiovascular MedicineProtein BindingArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function.

2009

AbstractWe describe a novel localization of C7 as a membrane-bound molecule on endothelial cells (ECs). Data obtained by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), Western blot analysis, Northern blot analysis, and mass spectrometry revealed that membrane-associated C7 (mC7) was indistinguishable from soluble C7 and was associated with vimentin on the cell surface. mC7 interacted with the other late complement components to form membrane-bound TCC (mTCC). Unlike the soluble SC5b-9, mTCC failed to stimulate ECs to express adhesion molecules, to secrete IL-8, and to induce albumin leakage through a monolayer of ECs, and more importantly protected ECs from the proinf…

ProteomicsVasculitisUmbilical VeinsVasculitiImmunologyComplementComplement; C7; endothelial cells; inflammationComplement Membrane Attack ComplexBiologyBiochemistryProinflammatory cytokineWestern blotmedicineHumansVimentinC7Interleukin 8Northern blotRNA MessengerMembrane ProteinCells CulturedGel electrophoresisEndothelial Cellmedicine.diagnostic_testCell adhesion moleculeComplement; endothelial cells; inflammationInterleukin-8Endothelial CellsMembrane ProteinsProteomicUmbilical VeinHematologyCell BiologyMolecular biologyComplement C7Endothelial stem cellCells Cultured; Complement C7; Complement Membrane Attack Complex; Endothelial Cells; Humans; Interleukin-8; Membrane Proteins; Proteomics; RNA Messenger; Umbilical Veins; Vasculitis; Vimentin; Hematology; Biochemistry; Cell Biology; Immunologyinflammationendothelial cellComplement membrane attack complexHuman
researchProduct

On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.

1995

Combined treatment with trypsin, cholesterol esterase, and neuraminidase transforms LDL, but not HDL or VLDL, to particles with properties akin to those of lipid extracted from atherosclerotic lesions. Single or double enzyme modifications, or treatment with phospholipase C, or simple vortexing are ineffective. Triple enzyme treatment disrupts the ordered and uniform structure of LDL particles, and gives rise to the formation of inhomogeneous lipid droplets 10-200 nm in diameter with a pronounced net negative charge, but lacking significant amounts of oxidized lipid. Enzymatically modified LDL (E-LDL), but not oxidatively modified LDL (ox-LDL), is endowed with potent complement-activating c…

Very low-density lipoproteinArteriosclerosisImmunologyNeuraminidaseComplement Membrane Attack Complexchemistry.chemical_compoundLipid dropletmedicineExtracellularImmunology and AllergyHumansTrypsinReceptors ImmunologicComplement ActivationGlycoproteinsReceptors Lipoproteinchemistry.chemical_classificationReceptors ScavengerPhospholipase CCholesterolMacrophagesMembrane ProteinsComplement C3Complement System ProteinsArticlesScavenger Receptors Class BSterol EsteraseTrypsinLipid MetabolismLipoproteins LDLEnzymechemistryBiochemistryLow-density lipoproteinlipids (amino acids peptides and proteins)medicine.drugFoam CellsThe Journal of experimental medicine
researchProduct

The Complement System: Activation and Control

1985

One of the hallmarks of immunology has been analysis and characterization of the C system in biological fluids. It is composed of 11 proteins of the “classical” pathway:1 C1q, C1r, C1s, C4, C2, C3, C5, C6, C7, C8, and C9. There are three proteins of the “alternative” pathway (IUIS-WHO Nomenclature Committee 1981) B, D, and P. Finally, there are four control proteins: C1 inhibitor (Cl¯ INH) and C4b binding protein (C4b-bp) for the classical pathway, I (C3b inactivator or C3b INA) and H (β1 or C3b INA accelerator) for the alternative pathway, and anaphylatoxin inactivator. Due to the dramatic advances in protein chemistry, these 19 distinct serum proteins have been highly purified and charact…

biologyC4b-binding proteinChemistrychemical and pharmacologic phenomenaBlood proteinsComplement systemC1-inhibitorClassical complement pathwayBiochemistryImmunologybiology.proteinAlternative complement pathwayLysine carboxypeptidaseComplement membrane attack complex
researchProduct

Is cell salvage safe in liver resection? A pilot study

2007

Abstract Study Objective To investigate the quality of cell salvaged (CS) blood in patients undergoing hemihepatectomy (study group) and compare it with CS-blood from aortic surgery (control group). Design Observational study. Setting Operating room in a university hospital. Measurements 6 patients undergoing hemihepatectomy or aortobifemoral bypass with intraoperative blood loss of more than 800 mL. Samples were drawn from the central venous catheter, from the reservoir of a CS recovery system, and from the processed blood in each patient to determine interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor (TNF), complement C3a, and the terminal complement complex C5b-9. Microbiological ana…

medicine.medical_specialtyBlood transfusionmedicine.medical_treatmentCellPilot ProjectsComplement Membrane Attack ComplexResectionBlood Transfusion AutologousmedicineHepatectomyHumansInterleukin-6business.industryInterleukin-8InterleukinBacterial InfectionsInterleukin-10Complement systemSurgeryAnesthesiology and Pain Medicinemedicine.anatomical_structureCytokineComplement C3aErythrocyte TransfusionbusinessAnaerobic exerciseCentral venous catheterJournal of Clinical Anesthesia
researchProduct

Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rab…

1996

Objective: The complement system has been suggested to play a role in reperfusion injury which may result from an enhanced destruction of myocardial tissue or from an impairment of reflow. We investigated the influence of the C5b-9 complement complex on infarct size, reflow and arrhythmogenesis. Methods: Twenty-eight C6-competent rabbits and 18 rabbits with congenital C6 deficiency were subjected to either 30 min or 2 h of coronary artery occlusion followed by reperfusion. C6 deficiency was confirmed by the complement titration test and immunohistology. The triphenyl tetrazolium chloride method was used to delineate infarct size. Reflow into infarcted areas was evaluated histologically afte…

medicine.medical_specialtyTime FactorsPhysiologyMyocardial InfarctionIschemiaInfarctionMyocardial Reperfusion InjuryComplement Membrane Attack ComplexElectrocardiographyReperfusion therapyPhysiology (medical)Internal medicinemedicineAnimalscardiovascular diseasesComplement Activationbusiness.industryArrhythmias Cardiacmedicine.diseaseImmunohistochemistryComplement C6Complement systemRegional Blood FlowCoronary occlusionNo reflow phenomenoncardiovascular systemCardiologyRabbitsCardiology and Cardiovascular MedicineComplement membrane attack complexbusinessReperfusion injuryCardiovascular Research
researchProduct

Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human u…

2000

Aims/hypothesis. This study examines whether increased glucose concentrations are responsible for a decreased expression of membrane regulators of complement activation molecules. The effect of high glucose in determining an increase in membrane attack complex deposition on endothelial cells was also investigated. Methods. Endothelial cells were isolated from umbilical cord tissue, cultured in the presence of increased concentrations of glucose, and the expression of CD46, CD55, and CD59 was detected by ELISA (enzyme-linked immunosorbent assay) and by flow cytometry. Glucose-treated endothelial cells were also incubated with antiendothelial cell antibodies and fresh complement to assess the…

medicine.medical_specialtyUmbilical VeinsEndotheliumGlycosylphosphatidylinositolsEndocrinology Diabetes and MetabolismCellCD59 AntigensCD59Complement Membrane Attack ComplexBiologyUmbilical veinMembrane Cofactor ProteinAntigens CDPregnancyInternal medicineInternal MedicinemedicineHumansComplement ActivationCells CulturedMembrane GlycoproteinsCD55 AntigensCD46Cell biologyComplement systemEndothelial stem cellEndocrinologymedicine.anatomical_structureGlucoseFemaleEndothelium VascularComplement membrane attack complexDiabetologia
researchProduct